Results of Antiviral Susceptibility and Replicative Capacity Assays of Novel HCMV Genetic Variants
| Gene . | Mutation . | Na . | Patient History . | Antiviral Susceptibility (RI)b . | |||
|---|---|---|---|---|---|---|---|
| GCV . | CDV . | FOS . | LMV . | ||||
| UL54 | G441S | 1 | CVID | 0.67 (±0.24) | 1 (±0.75) | 1.13 (±0.8) | … |
| UL54 | F460S | 1 | HSCT | 0.86 (±0.45) | 0.88 (±0.78) | 1.11 (±0.8) | … |
| UL54 | A543V | 2 | Kidney (2) | 1.5 (±0.1) | 10 (±5.37) | 1.21 (±0.27) | … |
| UL54 | R512C | 1 | Kidney | 1 | 1 | 0.74 | … |
| UL54 | A928T | 1 | cCMV + 2 HSCT | >3 | >3 | >3 | … |
| UL56 | F345L | 1 | HSCT | 1.42 (±1.07) | 1.67 (±46) | 0.98 (±0.04) | 0.99 (±0.04) |
| UL56 | P800L | 1 | HSCT | 0.23 | 0.13 | 1 | 1.11 |
| Gene . | Mutation . | Na . | Patient History . | Antiviral Susceptibility (RI)b . | |||
|---|---|---|---|---|---|---|---|
| GCV . | CDV . | FOS . | LMV . | ||||
| UL54 | G441S | 1 | CVID | 0.67 (±0.24) | 1 (±0.75) | 1.13 (±0.8) | … |
| UL54 | F460S | 1 | HSCT | 0.86 (±0.45) | 0.88 (±0.78) | 1.11 (±0.8) | … |
| UL54 | A543V | 2 | Kidney (2) | 1.5 (±0.1) | 10 (±5.37) | 1.21 (±0.27) | … |
| UL54 | R512C | 1 | Kidney | 1 | 1 | 0.74 | … |
| UL54 | A928T | 1 | cCMV + 2 HSCT | >3 | >3 | >3 | … |
| UL56 | F345L | 1 | HSCT | 1.42 (±1.07) | 1.67 (±46) | 0.98 (±0.04) | 0.99 (±0.04) |
| UL56 | P800L | 1 | HSCT | 0.23 | 0.13 | 1 | 1.11 |
Abbreviations: cCMV, congenital cytomegalovirus infection; CDV, cidofovir; CVID, common variable immunodeficiency; FOS, foscarnet; GCV, ganciclovir; HCMV, human cytomegalovirus; HSCT, hematopoietic stem cell transplant; LMV, letermovir; RI, resistance index.
NOTE: RI >3 is considered drug resistant and is indicated in bold.
Number of patients in whom the mutation was detected.
The RI is the half-maximal effective concentration ([EC50] µM) value for the mutant strain divided by the EC50 of the AD169 HCMV control strain. Each mutant was checked against different antiviral concentrations in triplicate. Each individual experiment was repeated 3 times for each mutant, except for R512C and P800L, which could only be performed once. Data are indicated as the mean of the 3 technical replicates.
Results of Antiviral Susceptibility and Replicative Capacity Assays of Novel HCMV Genetic Variants
| Gene . | Mutation . | Na . | Patient History . | Antiviral Susceptibility (RI)b . | |||
|---|---|---|---|---|---|---|---|
| GCV . | CDV . | FOS . | LMV . | ||||
| UL54 | G441S | 1 | CVID | 0.67 (±0.24) | 1 (±0.75) | 1.13 (±0.8) | … |
| UL54 | F460S | 1 | HSCT | 0.86 (±0.45) | 0.88 (±0.78) | 1.11 (±0.8) | … |
| UL54 | A543V | 2 | Kidney (2) | 1.5 (±0.1) | 10 (±5.37) | 1.21 (±0.27) | … |
| UL54 | R512C | 1 | Kidney | 1 | 1 | 0.74 | … |
| UL54 | A928T | 1 | cCMV + 2 HSCT | >3 | >3 | >3 | … |
| UL56 | F345L | 1 | HSCT | 1.42 (±1.07) | 1.67 (±46) | 0.98 (±0.04) | 0.99 (±0.04) |
| UL56 | P800L | 1 | HSCT | 0.23 | 0.13 | 1 | 1.11 |
| Gene . | Mutation . | Na . | Patient History . | Antiviral Susceptibility (RI)b . | |||
|---|---|---|---|---|---|---|---|
| GCV . | CDV . | FOS . | LMV . | ||||
| UL54 | G441S | 1 | CVID | 0.67 (±0.24) | 1 (±0.75) | 1.13 (±0.8) | … |
| UL54 | F460S | 1 | HSCT | 0.86 (±0.45) | 0.88 (±0.78) | 1.11 (±0.8) | … |
| UL54 | A543V | 2 | Kidney (2) | 1.5 (±0.1) | 10 (±5.37) | 1.21 (±0.27) | … |
| UL54 | R512C | 1 | Kidney | 1 | 1 | 0.74 | … |
| UL54 | A928T | 1 | cCMV + 2 HSCT | >3 | >3 | >3 | … |
| UL56 | F345L | 1 | HSCT | 1.42 (±1.07) | 1.67 (±46) | 0.98 (±0.04) | 0.99 (±0.04) |
| UL56 | P800L | 1 | HSCT | 0.23 | 0.13 | 1 | 1.11 |
Abbreviations: cCMV, congenital cytomegalovirus infection; CDV, cidofovir; CVID, common variable immunodeficiency; FOS, foscarnet; GCV, ganciclovir; HCMV, human cytomegalovirus; HSCT, hematopoietic stem cell transplant; LMV, letermovir; RI, resistance index.
NOTE: RI >3 is considered drug resistant and is indicated in bold.
Number of patients in whom the mutation was detected.
The RI is the half-maximal effective concentration ([EC50] µM) value for the mutant strain divided by the EC50 of the AD169 HCMV control strain. Each mutant was checked against different antiviral concentrations in triplicate. Each individual experiment was repeated 3 times for each mutant, except for R512C and P800L, which could only be performed once. Data are indicated as the mean of the 3 technical replicates.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
